351530-34-2

Upstream product

• 351530-29-5 4-methoxyphenyl O-[2-azido-4,6-O-benzylidene-2-deoxy-3-O-(8-levulinoyloxyoctyl)-β-D-galactopyranosyl]-(1->4)-2,3-di-O-(4-methylbenzoyl)-β-D-glucopyranoside 
• 351530-30-8 methyl [2-azido-4,6-O-benzylidene-2-deoxy-3-O-(8-levulinoyloxyoctyl)-β-D-galactopyranosyl]-(1->4)-[4-methoxyphenyl 2,3-di-O-(4-methylbenzoyl)-β-D-glucopyranosid]uronate 
• 50816-19-8 8-bromooctanol 
• 351530-31-9 methyl [2-acetamido-4,6-O-benzylidene-2-deoxy-3-O-(8-levulinoyloxyoctyl)-β-D-galactopyranosyl]-(1->4)-[4-methoxyphenyl 2,3-di-O-(4-methylbenzoyl)-β-D-glucopyranosid]uronate 

Relevant academic research and scientific papers

Synthesis of linear-type chondroitin clusters having a C8 spacer between disaccharide moieties and enzymatic transfer of D-glucuronic acid to the artificial glycans

Newly designed linear-type glycoclusters were synthesized which involve a chondroitin repeating disaccharide ligand and a hydrophobic octyl ether spacer. The spacer mimics the corresponding disaccharide unit. Repeating elongation of the pseudo-tetrasaccharide that was derived from the common cluster unit [→8)-octyl-(1→3)-β-D-GalNAc-(1→4)-β-D-GlcA-(1→] allowed the syntheses of up to the pseudo-decasaccharide analog of chondroitin. An enzymatic D-GlcA transfer at the non-reducing end of the synthesized artificial glycans by GlcATase II was observed.